

Figure 1A





Figure 2A



Corrigendum

JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition

Anna Sophia McKenney, Allison N. Lau, Amritha Varshini Hanasoge Somasundara, Barbara Spitzer, Andrew M. Intlekofer, Jihae Ahn, Kaitlyn Shank, Franck T. Rapaport, Minal A. Patel, Efthymia Papalexi, Alan H. Shih, April Chiu, Elizaveta Freinkman, Esra A. Akbay, Mya Steadman, Raj Nagaraja, Katharine Yen, Julie Teruya-Feldstein, Kwok-Kin Wong, Raajit Rampal, Matthew G. Vander Heiden, Craig B. Thompson, and Ross L. Levine

Original citation: *J Clin Invest.* 2018;128(2):789–804. <https://doi.org/10.1172/JCI94516>.

Citation for this corrigendum: *J Clin Invest.* 2018;128(10):4743. <https://doi.org/10.1172/JCI124920>.

Craig B. Thompson's conflict-of-interest statement was not included in the manuscript. The authors apologize for the oversight. The correct statement is below.

CBT is a founder of Agios Pharmaceuticals and a member of its scientific advisory board. He also serves on the board of directors of Merck and Charles River Laboratories.

The authors regret the error.